Search - tctmd.com

Displaying 161 - 180 of 193

Sort: Relevancy | Date

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

Interventional Cardiovascular Device Development: Considerations in Clinical Trial Implementation

June 10, 2015

News Industry News

DalCor Pharma licenses a late-stage investigational cardiovascular drug following major discovery by Montreal Heart Institute (MHI) scientists

June 08, 2015

News Daily News

Risk Stratification Before PCI Ups Use of Bleeding Avoidance Strategies in High-Risk Patients

L.A. McKeown

April 03, 2015

News Daily News

Meta-analyses Shed Light on the Impact of DAPT Duration

Caitlin E. Cox

April 03, 2015

News Daily News

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

L.A. McKeown

February 25, 2015

News Daily News

Long-term Ticagrelor Therapy Cost-Effective in US Patients

L.A. McKeown

February 02, 2015

News Daily News

ASCERT Cost Analysis: CABG More Expensive Than PCI but Offers Better Outcomes

L.A. McKeown

January 12, 2015

News Daily News

Real-World Study Shows Benefits of Treating Culprit Vessel Only in STEMI

Yael L. Maxwell

November 06, 2014

News Features

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Daily News

Majority of Stable CAD Patients Misunderstand Purpose of PCI

L.A. McKeown

October 03, 2014

Presentation TCT 2014

Personalized Medicine: A Look Through the Eyes of Our DNA

September 14, 2014

News Industry News

Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in U.S.

August 25, 2014

News Daily News

Preprocedural Patient Factors Useful for Predicting Poor Outcome Following TAVR

L.A. McKeown

June 03, 2014

Presentation

Induced Pluripotent Stem Cells: Implications for Personalized Medicine

Presenter: Lior Gepstein

December 02, 2013

Presentation

Overview of Personalized Cardiovascular Medicine

Presenter: Amir Lerman

December 01, 2013

Presentation TCT 2013

The Future: Migrating to an Era of Informatics, Big Data, and Personalized Medicine

Presenter: Robert Califf

October 30, 2013

News Daily News

For A-fib Patients, Aspirin on Top of Anticoagulation Raises Bleeding Risk

Caitlin E. Cox

July 25, 2013

News Daily News

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

L.A. McKeown

January 13, 2013

Advertisement

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Interventional Cardiovascular Device Development: Considerations in Clinical Trial Implementation

DalCor Pharma licenses a late-stage investigational cardiovascular drug following major discovery by Montreal Heart Institute (MHI) scientists

Risk Stratification Before PCI Ups Use of Bleeding Avoidance Strategies in High-Risk Patients

Meta-analyses Shed Light on the Impact of DAPT Duration

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

Long-term Ticagrelor Therapy Cost-Effective in US Patients

ASCERT Cost Analysis: CABG More Expensive Than PCI but Offers Better Outcomes

Real-World Study Shows Benefits of Treating Culprit Vessel Only in STEMI

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Majority of Stable CAD Patients Misunderstand Purpose of PCI

Personalized Medicine: A Look Through the Eyes of Our DNA

Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in U.S.

Preprocedural Patient Factors Useful for Predicting Poor Outcome Following TAVR

Induced Pluripotent Stem Cells: Implications for Personalized Medicine

Overview of Personalized Cardiovascular Medicine

The Future: Migrating to an Era of Informatics, Big Data, and Personalized Medicine

For A-fib Patients, Aspirin on Top of Anticoagulation Raises Bleeding Risk

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content